Publication at Faculty of Medicine in Pilsen |
2016
Abstract
Targeted therapy of lung cancer has brought significant improvement in prognosis for a lot of patients with EGFR-sensitive mutations and ALK translocations. Other clinical studies have shown ROS1 translocation as another potential target.
Our case report brings probably the first successful use of crizotininib in a patient with ROS1 translocation in the Czech Republic. Treatment was tolerated well and persists continually.
During the control PET / CT scans partial regression of the disease was observed. ROS1 translocation becomes another promising target for our patients.
Therefore according to our opinion serious discussion about its inclusion among the basic genetic testing in lung adenocarcinomas should occur.